- Wednesday, August 2, 2023
8:00 AM – 8:15 AM ET
Welcome
8:00 AM – 8:15 AM ET
WelcomeCo-Chair: – Vanderbilt-Ingram Cancer Center
Co-Chair: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Co-Chair###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Co-Chair: – Vanderbilt-Ingram Cancer Center
### @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Co-Chair###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Co-Chair: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### 8:15 AM – 8:30 AM ET
1 - Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - Neoadjuvant Immunotherapy
8:15 AM – 8:30 AM ET
Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - Neoadjuvant ImmunotherapyPresenter: – Memorial Sloan Kettering Cancer Center
Yelena Y. Janjigian, MD – Memorial Sloan Kettering Cancer Center ### 1003985###Presenter###Chief, Gastrointestinal Oncology Service###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 8:30 AM – 8:45 AM ET
1 - Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - Adjuvant Immunotherapy
8:30 AM – 8:45 AM ET
Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - Adjuvant ImmunotherapyPresenter: – Kansas University Cancer Center
Anup Kasi, MD, MPH – Kansas University Cancer Center ### 1919511###Presenter###Associate Professor###Kansas University Cancer Center###Presenter: – Kansas University Cancer Center
### 8:45 AM – 9:00 AM ET
1 - Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers
8:45 AM – 9:00 AM ET
Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - DiscussionModerator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Moderator: – Vanderbilt-Ingram Cancer Center
Panelist: – Memorial Sloan Kettering Cancer Center
Panelist: – Kansas University Cancer Center
Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Moderator###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Yelena Y. Janjigian, MD – Memorial Sloan Kettering Cancer Center ### 1003985###Panelist###Chief, Gastrointestinal Oncology Service###Memorial Sloan Kettering Cancer Center###Panelist: – Memorial Sloan Kettering Cancer Center
### @@@ Anup Kasi, MD, MPH – Kansas University Cancer Center ### 1919511###Panelist###Associate Professor###Kansas University Cancer Center###Panelist: – Kansas University Cancer Center
### 9:00 AM – 9:15 AM ET
Break
9:00 AM – 9:15 AM ET
Break
9:15 AM – 9:30 AM ET
Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - Neoadjuvant Combined Immunotherapy
9:15 AM – 9:30 AM ET
Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - Neoadjuvant Combined ImmunotherapyPresenter: – Memorial Sloan Kettering Cancer Center
Yelena Y. Janjigian, MD – Memorial Sloan Kettering Cancer Center ### 1003985###Presenter###Chief, Gastrointestinal Oncology Service###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 9:30 AM – 9:45 AM ET
Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - Chemotherapy
9:30 AM – 9:45 AM ET
Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - ChemotherapyPresenter: – Kansas University Cancer Center
Anup Kasi, MD, MPH – Kansas University Cancer Center ### 1919511###Presenter###Associate Professor###Kansas University Cancer Center###Presenter: – Kansas University Cancer Center
### 9:45 AM – 10:00 AM ET
Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC)
9:45 AM – 10:00 AM ET
Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - DiscussionModerator: – Vanderbilt-Ingram Cancer Center
Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Panelist: – Memorial Sloan Kettering Cancer Center
Panelist: – Kansas University Cancer Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Moderator###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Yelena Y. Janjigian, MD – Memorial Sloan Kettering Cancer Center ### 1003985###Panelist###Chief, Gastrointestinal Oncology Service###Memorial Sloan Kettering Cancer Center###Panelist: – Memorial Sloan Kettering Cancer Center
### @@@ Anup Kasi, MD, MPH – Kansas University Cancer Center ### 1919511###Panelist###Associate Professor###Kansas University Cancer Center###Panelist: – Kansas University Cancer Center
### 10:00 AM – 10:15 AM ET
Break
10:00 AM – 10:15 AM ET
Break
10:15 AM – 11:15 AM ET
Non-CME Innvoation Theater
10:15 AM – 11:15 AM ET
Non-CME Innovation Theater
11:15 AM – 11:30 AM ET
Break
11:15 AM – 11:30 AM ET
Break
11:30 AM – 12:15 PM ET
Session 3: Targeted Agents in Colorectal Cancer: An UpdatePresenter: – University of Southern California
11:30 AM – 12:15 PM ET
Session 3: Targeted Agents in Colorectal Cancer: An UpdatePresenter: – University of Southern California
Heinz-Josef Lenz, MD – University of Southern California ### 989581###Presenter###Oncologist###University of Southern California###Presenter: – University of Southern California
### 12:15 PM – 12:30 PM ET
Break
12:15 PM – 12:30 PM ET
Break
12:30 PM – 1:15 PM ET
Session 4: Deciphering Appendiceal CancerPresenter: – Vanderbilt-Ingram Cancer Center
12:30 PM – 1:15 PM ET
Session 4: Deciphering Appendiceal CancerPresenter: – Vanderbilt-Ingram Cancer Center
Deepa Magge, MD, FACS – Vanderbilt-Ingram Cancer Center ### 1596159###Presenter###Assistant Professor of Surgery###Vanderbilt-Ingram Cancer Center###Presenter: – Vanderbilt-Ingram Cancer Center
### 1:15 PM – 1:30 PM ET
Break
1:15 PM – 1:30 PM ET
Break
1:30 PM – 2:30 PM ET
Non-CME Innvoation Theater
1:30 PM – 2:30 PM ET
Non-CME Innovation Theater
2:30 PM – 2:45 PM ET
Break
2:30 PM – 2:45 PM ET
Break
2:45 PM – 3:30 PM ET
Session 5: Clinical Trial Landscape Incorporating ctDNAPresenter: – Weill Cornell Medicine/NewYork-Presbyterian; Englander Institute of Precision Medicine
2:45 PM – 3:30 PM ET
Session 5: Clinical Trial Landscape Incorporating ctDNAPresenter: – Weill Cornell Medicine/NewYork-Presbyterian; Englander Institute of Precision Medicine
Pashtoon M. Kasi, MD, MS – Weill Cornell Medicine/NewYork-Presbyterian; Englander Institute of Precision Medicine ### 697458###Presenter###Director Colon Cancer Research; Director Liquid Biopsy Research###Weill Cornell Medicine/NewYork-Presbyterian; Englander Institute of Precision Medicine###Presenter: – Weill Cornell Medicine/NewYork-Presbyterian; Englander Institute of Precision Medicine
### 3:30 PM – 3:45 PM ET
Break
3:30 PM – 3:45 PM ET
Break
3:45 PM – 4:20 PM ET
6 - Session 6: Integration of Supportive Care
3:45 PM – 4:20 PM ET
Session 6: Integration of Supportive CarePresenter: – Memorial Sloan Kettering Cancer Center
Andrew Epstein, MD – Memorial Sloan Kettering Cancer Center ### 1880690###Presenter###Associate Attending ###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 4:20 PM – 4:30 PM ET
6 - Live Q&A
4:20 PM – 4:30 PM ET
Live Q&AModerator: – Vanderbilt-Ingram Cancer Center
Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Speaker: – Memorial Sloan Kettering Cancer Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Moderator###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Andrew Epstein, MD – Memorial Sloan Kettering Cancer Center ### 1880690###Speaker###Associate Attending ###Memorial Sloan Kettering Cancer Center###Speaker: – Memorial Sloan Kettering Cancer Center
### 4:30 PM – 4:45 PM ET
Break
4:30 PM – 4:45 PM ET
Break
4:45 PM – 5:20 PM ET
7 - Session 7: Perspectives on Clinical Trial Development in Anal Cancer
4:45 PM – 5:20 PM ET
Session 7: Perspectives on Clinical Trial Development in Anal CancerPresenter: – Vanderbilt-Ingram Cancer Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Presenter###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Presenter: – Vanderbilt-Ingram Cancer Center
### 5:20 PM – 5:30 PM ET
7 - Live Q&A
5:20 PM – 5:30 PM ET
Live Q&AModerator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Speaker: – Vanderbilt-Ingram Cancer Center
Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Moderator###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Speaker###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Speaker: – Vanderbilt-Ingram Cancer Center
### - Thursday, August 3, 2023
8:00 AM – 8:15 AM ET
Welcome
8:00 AM – 8:15 AM ET
WelcomeCo-Chair: – Vanderbilt-Ingram Cancer Center
Co-Chair: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Co-Chair###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Co-Chair: – Vanderbilt-Ingram Cancer Center
### @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Co-Chair###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Co-Chair: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### 8:15 AM – 8:30 AM ET
8 - Session 8: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided All RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Triplet Chemo + Bevacizumab
8:15 AM – 8:30 AM ET
Session 8: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided All RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Triplet Chemo + BevacizumabPresenter: – Fox Chase Cancer Center
Namrata (Neena) Vijayvergia, MD, FACP – Fox Chase Cancer Center ### 1544845###Presenter###Assistant Chief, Gastrointestinal Medical Oncology; Associate Professor###Fox Chase Cancer Center###Presenter: – Fox Chase Cancer Center
### 8:30 AM – 8:45 AM ET
8 - Session 8: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Doublet Chemo + Panitumumab
8:30 AM – 8:45 AM ET
Session 8: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Doublet Chemo + PanitumumabPresenter: – Department of Hematology and Oncology at Cleveland Clinic
Smitha Krishnamurthi, MD (she/her/hers) – Department of Hematology and Oncology at Cleveland Clinic ### 1691686###Presenter###Associate Professor###Department of Hematology and Oncology at Cleveland Clinic###Presenter: – Department of Hematology and Oncology at Cleveland Clinic
### she/her/hers8:45 AM – 9:00 AM ET
9 - Session 8: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Discussion
8:45 AM – 9:00 AM ET
Session 8: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - DiscussionModerator: – Vanderbilt-Ingram Cancer Center
Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Panelist: – Department of Hematology and Oncology at Cleveland Clinic
Panelist: – Fox Chase Cancer Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Moderator###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Smitha Krishnamurthi, MD (she/her/hers) – Department of Hematology and Oncology at Cleveland Clinic ### 1691686###Panelist###Associate Professor###Department of Hematology and Oncology at Cleveland Clinic###Panelist: – Department of Hematology and Oncology at Cleveland Clinic
### she/her/hers @@@ Namrata (Neena) Vijayvergia, MD, FACP – Fox Chase Cancer Center ### 1544845###Panelist###Assistant Chief, Gastrointestinal Medical Oncology; Associate Professor###Fox Chase Cancer Center###Panelist: – Fox Chase Cancer Center
### 9:00 AM – 9:15 AM ET
Break
9:00 AM – 9:15 AM ET
Break
9:15 AM – 9:50 AM ET
Session 9: Integrating Biomarkers into the Management of Gastric Cancer: A Focus on Molecular Testing and Targeted Treatment Strategies
9:15 AM – 9:50 AM ET
Session 9: Integrating Biomarkers into the Management of Gastric Cancer: A Focus on Molecular Testing and Targeted Treatment StrategiesPresenter: – Memorial Sloan Kettering Cancer Center
Yelena Y. Janjigian, MD – Memorial Sloan Kettering Cancer Center ### 1003985###Presenter###Chief, Gastrointestinal Oncology Service###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 9:50 AM – 10:00 AM ET
Live Q&A
9:50 AM – 10:00 AM ET
Live Q&AModerator: – Vanderbilt-Ingram Cancer Center
Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Speaker: – Memorial Sloan Kettering Cancer Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Moderator###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Yelena Y. Janjigian, MD – Memorial Sloan Kettering Cancer Center ### 1003985###Speaker###Chief, Gastrointestinal Oncology Service###Memorial Sloan Kettering Cancer Center###Speaker: – Memorial Sloan Kettering Cancer Center
### 10:00 AM – 10:15 AM ET
Break
10:00 AM – 10:15 AM ET
Break
10:15 AM – 11:15 AM ET
Non-CME Innvoation Theater
10:15 AM – 11:15 AM ET
Non-CME Innovation Theater
11:15 AM – 11:30 AM ET
Break
11:15 AM – 11:30 AM ET
Break
11:30 AM – 12:05 PM ET
10 - Session 10: Therapeutic Sequencing in Advanced Colorectal Cancer: New Strategies from Clinical Trial DataPresenter: – University of Arizona Cancer Center
11:30 AM – 12:05 PM ET
Session 10: Therapeutic Sequencing in Advanced Colorectal Cancer: New Strategies from Clinical Trial DataPresenter: – University of Arizona Cancer Center
Aaron J. Scott, MD – University of Arizona Cancer Center ### 2027555###Presenter###Associate Professor###University of Arizona Cancer Center###Presenter: – University of Arizona Cancer Center
### 12:05 PM – 12:15 PM ET
10 - Live Q&AModerator: – Vanderbilt-Ingram Cancer Center
Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Speaker: – University of Arizona Cancer Center
12:05 PM – 12:15 PM ET
Live Q&AModerator: – Vanderbilt-Ingram Cancer Center
Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Speaker: – University of Arizona Cancer Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Moderator###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Aaron J. Scott, MD – University of Arizona Cancer Center ### 2027555###Speaker###Associate Professor###University of Arizona Cancer Center###Speaker: – University of Arizona Cancer Center
### 12:15 PM – 12:30 PM ET
Break
12:15 PM – 12:30 PM ET
Break
12:30 PM – 1:05 PM ET
11 - Session 11: Updates from Recent MeetingsPresenter: – University Hospitals Leuven / KU Leuven
12:30 PM – 1:05 PM ET
Session 11: Updates from Recent MeetingsPresenter: – University Hospitals Leuven / KU Leuven
Eric Van Cutsem, MD, PhD (he/him/his) – University Hospitals Leuven / KU Leuven ### 697455###Presenter###Professor of Medicine###University Hospitals Leuven / KU Leuven###Presenter: – University Hospitals Leuven / KU Leuven
### he/him/his1:05 PM – 1:15 PM ET
11 - Live Q&AModerator: – Vanderbilt-Ingram Cancer Center
Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Speaker: – University Hospitals Leuven / KU Leuven
1:05 PM – 1:15 PM ET
Live Q&AModerator: – Vanderbilt-Ingram Cancer Center
Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Speaker: – University Hospitals Leuven / KU Leuven
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Moderator###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Eric Van Cutsem, MD, PhD (he/him/his) – University Hospitals Leuven / KU Leuven ### 697455###Speaker###Professor of Medicine###University Hospitals Leuven / KU Leuven###Speaker: – University Hospitals Leuven / KU Leuven
### he/him/his1:15 PM – 1:30 PM ET
Break
1:15 PM – 1:30 PM ET
Break
1:30 PM – 2:30 PM ET
Non-CME Innvoation Theater
1:30 PM – 2:30 PM ET
Non-CME Innovation Theater
2:30 PM – 2:45 PM ET
Break
2:30 PM – 2:45 PM ET
Break
2:45 PM – 3:00 PM ET
12 - Session 12: Debate: Pancreatic NETs: PRRT vs Chemotherapy - PRRT
2:45 PM – 3:00 PM ET
Session 12: Debate: Pancreatic NETs: PRRT vs Chemotherapy - PRRTPresenter: – The University of Texas MD Anderson Cancer Center
Arvind Dasari, MD – The University of Texas MD Anderson Cancer Center ### 1428669###Presenter###Associate Professor###The University of Texas MD Anderson Cancer Center###Presenter: – The University of Texas MD Anderson Cancer Center
### 3:00 PM – 3:15 PM ET
12 - Session 12: Debate: Pancreatic NETs: PRRT vs Chemotherapy - Chemotherapy
3:00 PM – 3:15 PM ET
Session 12: Debate: Pancreatic NETs: PRRT vs Chemotherapy - ChemotherapyPresenter: – Huntsman Cancer Institute at the University of Utah
Heloisa Soares, MD, PhD (she/her/hers) – Huntsman Cancer Institute at the University of Utah ### 1880692###Presenter###Associate Professor###Huntsman Cancer Institute at the University of Utah###Presenter: – Huntsman Cancer Institute at the University of Utah
### she/her/hers3:15 PM – 3:30 PM ET
12 - Session 12: Debate: Pancreatic NETs: PRRT vs Chemotherapy
3:15 PM – 3:30 PM ET
Session 12: Debate: Pancreatic NETs: PRRT vs Chemotherapy - DiscussionModerator: – Vanderbilt-Ingram Cancer Center
Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Panelist: – The University of Texas MD Anderson Cancer Center
Panelist: – Huntsman Cancer Institute at the University of Utah
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Moderator###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Arvind Dasari, MD – The University of Texas MD Anderson Cancer Center ### 1428669###Panelist###Associate Professor###The University of Texas MD Anderson Cancer Center###Panelist: – The University of Texas MD Anderson Cancer Center
### @@@ Heloisa Soares, MD, PhD (she/her/hers) – Huntsman Cancer Institute at the University of Utah ### 1880692###Panelist###Associate Professor###Huntsman Cancer Institute at the University of Utah###Panelist: – Huntsman Cancer Institute at the University of Utah
### she/her/hers3:30 PM – 3:45 PM ET
Break
3:30 PM – 3:45 PM ET
Break
3:45 PM – 4:20 PM ET
13 - Session 13: The Pillars of Cancer Wellness
3:45 PM – 4:20 PM ET
Session 13: The Pillars of Cancer WellnessPresenter: – Memorial Sloan Kettering Cancer Center
Gary E. Deng, MD, PhD – Memorial Sloan Kettering Cancer Center ### 1699641###Presenter###Medical Director, Integrative Medicine Service###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 4:20 PM – 4:30 PM ET
13 - Live Q&A
4:20 PM – 4:30 PM ET
Live Q&AModerator: – Vanderbilt-Ingram Cancer Center
Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Speaker: – Memorial Sloan Kettering Cancer Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Moderator###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Gary E. Deng, MD, PhD – Memorial Sloan Kettering Cancer Center ### 1699641###Speaker###Medical Director, Integrative Medicine Service###Memorial Sloan Kettering Cancer Center###Speaker: – Memorial Sloan Kettering Cancer Center
### 4:30 PM – 4:45 PM ET
Break
4:30 PM – 4:45 PM ET
Break
4:45 PM – 5:20 PM ET
14 - Session 14: The Power of Patient Advocacy
4:45 PM – 5:20 PM ET
Session 14: The Power of Patient AdvocacyPresenter: – Fight Colorectal Cancer
Anjee Davis, MPPA (she/her/hers) – Fight Colorectal Cancer ### 1867780###Presenter###President###Fight Colorectal Cancer###Presenter: – Fight Colorectal Cancer
### she/her/hers5:20 PM – 5:30 PM ET
14 - Live Q&A
5:20 PM – 5:30 PM ET
Live Q&AModerator: – Vanderbilt-Ingram Cancer Center
Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Speaker: – Fight Colorectal Cancer
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Moderator###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Anjee Davis, MPPA (she/her/hers) – Fight Colorectal Cancer ### 1867780###Speaker###President###Fight Colorectal Cancer###Speaker: – Fight Colorectal Cancer
### she/her/hers- Friday, August 4, 2023
9:00 AM – 9:15 AM ET
Welcome
9:00 AM – 9:15 AM ET
WelcomeCo-Chair: – Vanderbilt-Ingram Cancer Center
Co-Chair: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Co-Chair###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Co-Chair: – Vanderbilt-Ingram Cancer Center
### @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Co-Chair###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Co-Chair: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### 9:15 AM – 9:30 AM ET
18 - Session 15: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - FOLFIRINOX
9:15 AM – 9:30 AM ET
Session 15: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - FOLFIRINOXPresenter: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Presenter###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Presenter: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### 9:30 AM – 9:45 AM ET
18 - Session 15: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - NALIRIFOX
9:30 AM – 9:45 AM ET
Session 15: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - NALIRIFOXPresenter: – MD Anderson Cancer Center, The University of Texas
Milind M. Javle, MD – MD Anderson Cancer Center, The University of Texas ### 944699###Presenter###Professor of Medicine###MD Anderson Cancer Center, The University of Texas###Presenter: – MD Anderson Cancer Center, The University of Texas
### 9:45 AM – 10:00 AM ET
18 - Session 15: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer
9:45 AM – 10:00 AM ET
Session 15: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - DiscussionModerator: – Vanderbilt-Ingram Cancer Center
Panelist: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Panelist: – MD Anderson Cancer Center, The University of Texas
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Panelist###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Panelist: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Milind M. Javle, MD – MD Anderson Cancer Center, The University of Texas ### 944699###Panelist###Professor of Medicine###MD Anderson Cancer Center, The University of Texas###Panelist: – MD Anderson Cancer Center, The University of Texas
### 10:00 AM – 10:15 AM ET
Break
10:00 AM – 10:15 AM ET
Break
10:15 AM – 10:30 AM ET
15 - Session 16: Debate: Is There a Role for Radiation Therapy in Borderline-Resectable Pancreatic Cancer? Yes vs No - Yes
10:15 AM – 10:30 AM ET
Session 16: Debate: Is There a Role for Radiation Therapy in Borderline-Resectable Pancreatic Cancer? Yes vs No - YesPresenter: – Northwell Health Cancer Institute
Joseph Herman, MD, MSc, MHCM (he/him/his) – Northwell Health Cancer Institute ### 1849663###Presenter###Director of Clinical Research###Northwell Health Cancer Institute###Presenter: – Northwell Health Cancer Institute
### he/him/his10:30 AM – 10:45 AM ET
15 - Session 16: Debate: Is There A Role for Radiation Therapy in Borderline-Resectable Pancreatic Cancer? Yes vs No - No
10:30 AM – 10:45 AM ET
Session 16: Debate: Is There A Role for Radiation Therapy in Borderline-Resectable Pancreatic Cancer? Yes vs No - NoPresenter: – Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center
Lisa Kachnic, MD (she/her/hers) – Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center ### 1849664###Presenter###Professor and Chair, Department of Radiation Oncology###Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center###Presenter: – Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center
### she/her/hers10:45 AM – 11:00 AM ET
15 - Session 16: Debate: Is There A Role for Radiation Therapy in Borderline-Resectable Pancreatic Cancer? Yes vs No - Discussion
10:45 AM – 11:00 AM ET
Session 16: Debate: Is There A Role for Radiation Therapy in Borderline-Resectable Pancreatic Cancer? Yes vs No - DiscussionModerator: – Vanderbilt-Ingram Cancer Center
Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Panelist: – Northwell Health Cancer Institute
Panelist: – Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Moderator###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Joseph Herman, MD, MSc, MHCM (he/him/his) – Northwell Health Cancer Institute ### 1849663###Panelist###Director of Clinical Research###Northwell Health Cancer Institute###Panelist: – Northwell Health Cancer Institute
### he/him/his @@@ Lisa Kachnic, MD (she/her/hers) – Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center ### 1849664###Panelist###Professor and Chair, Department of Radiation Oncology###Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center###Panelist: – Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center
### she/her/hers11:00 AM – 11:15 AM ET
Break
11:00 AM – 11:15 AM ET
Break
11:15 AM – 11:50 AM ET
19 - Session 17: Improving the Management of Cholangiocarcinoma: Adopting Recent NCCN Guidelines to Improve Patient Care in Diagnosis, Molecular Testing, and Targeted Treatment Strategies
11:15 AM – 11:50 AM ET
Session 17: Improving the Management of Cholangiocarcinoma: Adopting Recent NCCN Guidelines to Improve Patient Care in Diagnosis, Molecular Testing, and Targeted Treatment StrategiesPresenter: – MD Anderson Cancer Center, The University of Texas
Milind M. Javle, MD – MD Anderson Cancer Center, The University of Texas ### 944699###Presenter###Professor of Medicine###MD Anderson Cancer Center, The University of Texas###Presenter: – MD Anderson Cancer Center, The University of Texas
### 11:50 AM – 12:00 PM ET
19 - Live Q&A
11:50 AM – 12:00 PM ET
Live Q&AModerator: – Vanderbilt-Ingram Cancer Center
Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Speaker: – MD Anderson Cancer Center, The University of Texas
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Moderator###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Milind M. Javle, MD – MD Anderson Cancer Center, The University of Texas ### 944699###Speaker###Professor of Medicine###MD Anderson Cancer Center, The University of Texas###Speaker: – MD Anderson Cancer Center, The University of Texas
### 12:15 PM – 12:30 PM ET
Break
12:15 PM – 12:30 PM ET
Break
12:30 PM – 1:05 PM ET
21 - Session 18: Rising Incidence of Early-Onset GI Malignancies: Pancreatic, CRC, and Gastric
12:30 PM – 1:05 PM ET
Session 18: Rising Incidence of Early-Onset GI Malignancies: Pancreatic, CRC, and GastricPresenter: – Vanderbilt-Ingram Cancer Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Presenter###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Presenter: – Vanderbilt-Ingram Cancer Center
### 1:05 PM – 1:15 PM ET
21 - Live Q&A
1:05 PM – 1:15 PM ET
Live Q&AModerator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Speaker: – Vanderbilt-Ingram Cancer Center
Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Moderator###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Speaker###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Speaker: – Vanderbilt-Ingram Cancer Center
### 1:15 PM – 1:30 PM ET
Break
1:15 PM – 1:30 PM ET
Break
1:30 PM – 2:15 PM ET
Session 19: Determination of Treatment Patterns in HCCPresenter: – Memorial Sloan Kettering Cancer Center
1:30 PM – 2:15 PM ET
Session 19: Determination of Treatment Patterns in HCCPresenter: – Memorial Sloan Kettering Cancer Center
Ghassan K. Abou-Alfa, MD, MBA – Memorial Sloan Kettering Cancer Center ### 697827###Presenter###Professor###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 2:15 PM – 2:30 PM ET
Break
2:15 PM – 2:30 PM ET
Break
2:30 PM – 3:15 PM ET
Session 20: Role of Interventional Radiology in the Management of NETsPresenter: – Stanford School of Medicine
2:30 PM – 3:15 PM ET
Session 20: Role of Interventional Radiology in the Management of NETsPresenter: – Stanford School of Medicine
Nishita Kothary, MD – Stanford School of Medicine ### 1001596###Presenter###Professor###Stanford School of Medicine###Presenter: – Stanford School of Medicine
### 3:15 PM – 3:30 PM ET
Break
3:15 PM – 3:30 PM ET
Break
3:30 PM – 4:15 PM ET
20 - Session 21: Significance of Cancer Genetics
3:30 PM – 4:15 PM ET
Session 21: Significance of Cancer GeneticsPresenter: – University of Chicago
Sonia Kupfer, MD (she/her/hers) – University of Chicago ### 1849665###Presenter###Associate Professor of Medicine###University of Chicago###Presenter: – University of Chicago
### she/her/hers4:15 PM – 4:20 PM ET
20 - Closing Remarks
4:15 PM – 4:20 PM ET
Closing RemarksCo-Chair: – Vanderbilt-Ingram Cancer Center
Co-Chair: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Co-Chair###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Co-Chair: – Vanderbilt-Ingram Cancer Center
### @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Co-Chair###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Co-Chair: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### - On Demand
On-Demand
Augmenting Standard Treatment Options in Pancreatic CancerPresenter: – The University of Arizona Cancer Center
On-Demand
Augmenting Standard Treatment Options in Pancreatic CancerPresenter: – The University of Arizona Cancer Center
Rachna Shroff, MD (she/her/hers) – The University of Arizona Cancer Center ### 1691690###Presenter###Interim Chief, Division of Hematology/Oncology
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
Associate Dean, Clinical and Translational Research, UA-COM
Associate Professor of Medicine
University of Arizona Cancer Center (UACC)
University of Arizona College of Medicine – Tucson (UA-COM)###The University of Arizona Cancer Center###Presenter: – The University of Arizona Cancer Center
### she/her/hersOn-Demand
Colon Cancer Update in Adjuvant TherapyPresenter: – Harvard Medical School; Massachusetts General Hospital
On-Demand
Colon Cancer Update in Adjuvant TherapyPresenter: – Harvard Medical School; Massachusetts General Hospital
Aparna Parikh, MD, MS – Harvard Medical School; Massachusetts General Hospital ### 1422860###Presenter###Assistant Professor of Medicine; Medical Director, Center for Young Adult Colorectal Cancer###Harvard Medical School; Massachusetts General Hospital###Presenter: – Harvard Medical School; Massachusetts General Hospital
### On-Demand
Critical Pathways in Metastatic Colorectal CancerPresenter: – MGH Cancer Center
On-Demand
Critical Pathways in Metastatic Colorectal CancerPresenter: – MGH Cancer Center
Ryan Corcoran, MD, PhD (he/him/his) – MGH Cancer Center ### 1007383###Presenter###Director, GI Cancer Center Program###MGH Cancer Center###Presenter: – MGH Cancer Center
### he/him/hisOn-Demand
Emerging Targets in Upper Gastrointestinal Tract (UGI) Cancers
On-Demand
Emerging Targets in Upper Gastrointestinal Tract (UGI) CancersPresenter: – Mass General Cancer Center
Sam Klempner, MD (he/him/his) – Mass General Cancer Center ### 1560485###Presenter###Associate Professor###Mass General Cancer Center###Presenter: – Mass General Cancer Center
### he/him/hisOn-Demand
The Emerging Role of Checkpoint Inhibitor Therapy in Locally Advanced Esophagogastric CancerPresenter: – University of Pennsylvania, Abramson Cancer Center
On-Demand
The Emerging Role of Checkpoint Inhibitor Therapy in Locally Advanced Esophagogastric CancerPresenter: – University of Pennsylvania, Abramson Cancer Center
Jennifer R. Eads, MD (she/her/hers) – University of Pennsylvania, Abramson Cancer Center ### 904443###Presenter###Associate Professor of Medicine###University of Pennsylvania, Abramson Cancer Center###Presenter: – University of Pennsylvania, Abramson Cancer Center
### she/her/hers
